Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Pelthos Therapeutics Inc.AMEX: PTHS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $186K fell 4.3% year over year, behind the +34.5% change in trailing-twelve-month research & development. Sequentially, it fell 50.3% from the prior quarter. Over 3 fiscal years it compounded at +46.4% a year.

Context

  • Research & development amounted to 7.3% of revenue in FY2025.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -4.3% toward the trailing-twelve-month pace of +34.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$186K-50.3% QoQ
Last fiscal yearDec 2025
$1.23M+4.1% YoY
LTMMar 2026
$1.22M+34.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.3%——
1 year+4.1%——
3-year CAGR+46.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
1.23M USD
Year-over-year change
+4.1%
4-year CAGR
+55.7%

Research & Development vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's LTM Mar 2026 research & development of $1.22M is the 3rd highest of the 4 companies compared; the peer median is $9.2M.
  • Its year-over-year change of +34.5% is the highest of 4, against a peer median of -13.4%.
  • Research & development amounts to 4.4% of revenue for PTHS.
PTHS Competitors Peer median
Research & Development for PTHS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CINGCingulate Inc.LTM Mar 2026$9.74M -1.3%+2.8%—
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$9.2M -13.4%-21.9%—
PTHSPelthos Therapeutics Inc.LTM Mar 2026$1.22M +34.5%+46.4%4.4%
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026$496.84K -28.9%-42.6%—
Peer median (excluding PTHS) $9.2M-13.4%-21.9%—

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000016.8M
Cost of Revenue00009.37M
Gross Profit00007.43M
Gross Margin————44.2%
Research & Development209.05K391.73K2.58M1.18M1.23M
Selling, General & Admin629.95K1.93M4.28M6.39M37.08M
Operating Expenses839K2.32M6.86M7.57M39.86M
Depreciation & Amortization00002.29M
EBITDA(595.13K)(2.32M)(6.86M)(7.17M)(45.41M)
EBITDA Margin————-270.4%
Operating Income(839K)(2.32M)(6.86M)(7.57M)(32.43M)
Operating Margin————-193.1%
Interest Income00005K
Interest Expense253140.43K518.51K786.39K3.01M
Other Income / Expenses243.61K(140.43K)(518.51K)(383.89K)(18.28M)
Income Before Tax(595.39K)(2.46M)(7.38M)(7.96M)(50.71M)
Pre-Tax Margin————-301.9%
Income Tax Expense0000(7.39M)
Net Income(595.39K)(2.46M)(7.38M)(7.96M)(43.32M)
Net Margin————-257.9%
EPS (Basic)(1.00)(4.26)(12.80)(13.54)(23.04)
EPS (Diluted)(1.00)(4.26)(12.80)(13.54)(23.04)
Weighted Avg Shares576.75K576.75K576.75K587.62K1.88M
Weighted Avg Shares (Diluted)576.75K576.75K576.75K587.62K1.88M

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.